

MOROCCO, 2 registries (2005-2012)

	Number of cases							Percentage				Incidence rates per million person-years								MV % 0-19	DCO % 0-19		
	Age group							0-14		0-19		Age-specific					Cumulative						
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14	ASR	0-19			0-14	0-19
I LEUKAEMIA	5	62	64	55	82	186	268	16.2	100.0	15.9	100.0	8.4	26.0	22.0	17.9	25.3	21.0	22.0	312	438	96.6	3.4	
a. Lymphoid	2	49	43	34	40	128	168	11.2	68.8	10.0	62.7	3.4	20.6	14.8	11.0	12.3	14.6	14.1	215	276	95.8	4.2	
b. Acute myeloid	2	11	13	14	33	40	73	3.5	21.5	4.3	27.2	3.4	4.6	4.5	4.5	10.2	4.5	5.7	67	118	100.0	0.0	
c. CMD	0	0	2	5	6	7	13	0.6	3.8	0.8	4.9	-	-	0.7	1.6	1.8	0.7	1.0	12	21	100.0	0.0	
d. MDS & other	0	0	2	0	1	2	3	0.2	1.1	0.2	1.1	-	-	0.7	-	0.3	0.2	0.2	3	5	66.7	33.3	
e. Unspecified	1	2	4	2	2	9	11	0.8	4.8	0.7	4.1	1.7	0.8	1.4	0.6	0.6	1.0	0.9	15	18	90.9	9.1	
II LYMPHOMA & RELATED	4	33	75	75	151	187	338	16.3	100.0	20.0	100.0	6.7	13.9	25.8	24.4	46.5	20.2	26.1	313	545	99.4	0.6	
a. Hodgkin	0	10	31	38	86	79	165	6.9	42.2	9.8	48.8	-	4.2	10.7	12.3	26.5	8.3	12.4	132	264	99.4	0.6	
b. Non-Hodgkin except BL	3	7	18	22	51	50	101	4.4	26.7	6.0	29.9	5.0	2.9	6.2	7.1	15.7	5.4	7.7	83	162	100.0	0.0	
c. Burkitt (BL)	1	13	24	13	9	51	60	4.5	27.3	3.6	17.8	1.7	5.5	8.2	4.2	2.8	5.7	5.0	86	100	98.3	1.7	
d. Lymphoreticular	0	2	1	0	0	3	3	0.3	1.6	0.2	0.9	-	0.8	0.3	-	-	0.4	0.3	5	5	100.0	0.0	
e. Unspecified	0	1	1	2	5	4	9	0.3	2.1	0.5	2.7	-	0.4	0.3	0.6	1.5	0.4	0.7	7	14	100.0	0.0	
III CNS NEOPLASMS †	6	45	71	51	34	173	207	15.1	100.0	12.3	100.0	10.1	18.9	24.4	16.6	10.5	19.3	17.3	291	343	94.7	2.9	
a. Ependymoma	0	13	11	5	5	29	34	2.5	16.8	2.0	16.4	-	5.5	3.8	1.6	1.5	3.4	3.0	49	57	97.1	2.9	
b. Astrocytoma	1	6	20	17	14	44	58	3.8	25.4	3.4	28.0	1.7	2.5	6.9	5.5	4.3	4.7	4.6	74	95	100.0	0.0	
c. CNS embryonal	2	15	28	13	6	58	64	5.1	33.5	3.8	30.9	3.4	6.3	9.6	4.2	1.8	6.5	5.5	98	107	98.4	1.6	
d. Other gliomas	0	5	4	3	3	12	15	1.0	6.9	0.9	7.2	-	2.1	1.4	1.0	0.9	1.4	1.3	20	25	66.7	0.0	
e. Other specified	0	1	1	9	5	11	16	1.0	6.4	0.9	7.7	-	0.4	0.3	2.9	1.5	1.1	1.2	18	26	100.0	0.0	
f. Unspecified CNS	3	5	7	4	1	19	20	1.7	11.0	1.2	9.7	5.0	2.1	2.4	1.3	0.3	2.2	1.8	32	34	80.0	20.0	
IV NEUROBLASTOMA	6	45	19	9	4	79	83	6.9	100.0	4.9	100.0	10.1	18.9	6.5	2.9	1.2	9.6	7.7	133	139	96.4	0.0	
a. (Ganglio)neuroblastoma	6	45	19	9	4	79	83	6.9	100.0	4.9	100.0	10.1	18.9	6.5	2.9	1.2	9.6	7.7	133	139	96.4	0.0	
b. Peripheral nervous	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
V RETINOBLASTOMA	5	60	6	1	0	72	72	6.3	100.0	4.3	100.0	8.4	25.2	2.1	0.3	-	9.2	7.1	121	121	97.2	0.0	
VI RENAL TUMOURS	4	60	33	5	3	102	105	8.9	100.0	6.2	100.0	6.7	25.2	11.3	1.6	0.9	12.5	9.9	172	177	100.0	0.0	
a. Nephroblastoma	3	55	30	5	2	93	95	8.1	91.2	5.6	90.5	5.0	23.1	10.3	1.6	0.6	11.3	8.9	157	160	100.0	0.0	
b. Renal carcinoma	1	4	2	0	1	7	8	0.6	6.9	0.5	7.6	1.7	1.7	0.7	-	0.3	0.9	0.7	12	13	100.0	0.0	
c. Unspecified	0	1	1	0	0	2	2	0.2	2.0	0.1	1.9	-	0.4	0.3	-	-	0.2	0.2	3	3	100.0	0.0	
VII HEPATIC TUMOURS	2	6	0	3	0	11	11	1.0	100.0	0.7	100.0	3.4	2.5	-	1.0	-	1.3	1.0	18	18	90.9	9.1	
a. Hepatoblastoma	2	6	0	0	0	8	8	0.7	72.7	0.5	72.7	3.4	2.5	-	-	-	1.0	0.8	13	13	87.5	12.5	
b. Hepatic carcinoma	0	0	0	3	0	3	3	0.3	27.3	0.2	27.3	-	-	-	1.0	-	0.3	0.2	5	5	100.0	0.0	
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
VIII BONE TUMOURS	2	7	24	52	78	85	163	7.4	100.0	9.7	100.0	3.4	2.9	8.2	16.9	24.0	8.7	12.2	141	261	100.0	0.0	
a. Osteosarcoma	0	3	6	23	52	32	84	2.8	37.6	5.0	51.5	-	1.3	2.1	7.5	16.0	3.2	6.1	53	133	100.0	0.0	
b. Chondrosarcoma	0	0	0	0	1	0	1	-	-	0.1	0.6	-	-	-	-	0.3	-	0.1	-	2	2	100.0	0.0
c. Ewing & related	2	3	17	23	20	45	65	3.9	52.9	3.9	39.9	3.4	1.3	5.8	7.5	6.2	4.7	5.0	75	106	100.0	0.0	
d. Other specified	0	1	1	0	2	2	4	0.2	2.4	0.2	2.5	-	0.4	0.3	-	0.6	0.2	0.3	3	6	100.0	0.0	
e. Unspecified	0	0	0	6	3	6	9	0.5	7.1	0.5	5.5	-	-	-	1.9	0.9	0.6	0.6	10	14	100.0	0.0	
IX SOFT TISSUE SARCOMA	1	35	20	30	47	86	133	7.5	100.0	7.9	100.0	1.7	14.7	6.9	9.7	14.5	9.7	10.8	144	216	100.0	0.0	
a. Rhabdomyosarcoma	1	25	16	15	6	57	63	5.0	66.3	3.7	47.4	1.7	10.5	5.5	4.9	1.8	6.6	5.5	96	105	100.0	0.0	
b. Fibrosarcoma	0	2	0	2	6	4	10	0.3	4.7	0.6	7.5	-	0.8	-	0.6	1.8	0.4	0.8	7	16	100.0	0.0	
c. Kaposi sarcoma	0	0	0	0	1	0	1	-	-	0.1	0.8	-	-	-	-	0.3	-	0.1	-	2	2	100.0	0.0
d. Other specified	0	3	2	9	24	14	38	1.2	16.3	2.3	28.6	-	1.3	0.7	2.9	7.4	1.5	2.8	23	60	100.0	0.0	
e. Unspecified	0	5	2	4	10	11	21	1.0	12.8	1.2	15.8	-	2.1	0.7	1.3	3.1	1.2	1.7	18	34	100.0	0.0	
X GERM CELL TUMOURS	2	12	0	5	15	19	34	1.7	100.0	2.0	100.0	3.4	5.0	-	1.6	4.6	2.3	2.8	32	55	100.0	0.0	
a. CNS germ cell ‡	0	1	0	2	1	3	4	0.3	15.8	0.2	11.8	-	0.4	-	0.6	0.3	0.3	0.3	5	6	100.0	0.0	
b. Other extragonadal	1	5	0	1	3	7	10	0.6	36.8	0.6	29.4	1.7	2.1	-	0.3	0.9	0.9	0.9	12	16	100.0	0.0	
c. Gonadal germ cell	0	6	0	2	3	8	11	0.7	42.1	0.7	32.4	-	2.5	-	0.6	0.9	1.0	1.0	13	18	100.0	0.0	
d. Gonadal carcinoma	0	0	0	0	4	0	4	-	-	0.2	11.8	-	-	-	-	-	-	0.3	-	6	6	100.0	0.0
e. Unspecified gonadal	1	0	0	0	4	1	5	0.1	5.3	0.3	14.7	1.7	-	-	-	1.2	0.1	0.4	2	8	100.0	0.0	
XI CARCINOMA & MELANOMA	12	6	16	63	111	97	208	8.5	100.0	12.3	100.0	20.2	2.5	5.5	20.5	34.2	10.1	15.5	160	331	100.0	0.0	
a. Adrenocortical	0	0	0	1	0	1	1	0.1	1.0	0.1	0.5	-	-	-	0.3	-	0.1	0.1	2	2	100.0	0.0	
b. Thyroid	0	1	3	4	23	8	31	0.7	8.2	1.8	14.9	-	0.4	1.0	1.3	7.1	0.8	2.2	13	49	100.0	0.0	
c. Nasopharyngeal	1	0	1	27	36	29	65	2.5	29.9	3.9	31.3	1.7	-	0.3	8.8	11.1	2.8	4.7	47	103	100.0	0.0	
d. Melanoma	0	0	0	0	5	0	5	-	-	0.3	2.4	-	-	-	-	1.5	-	0.3	-	8	8	100.0	0.0
e. Skin carcinoma	1	4	10	23	19	38	57	3.3	39.2	3.4	27.4	1.7	1.7	3.4	7.5	5.9	3.9	4.4	63	92	100.0	0.0	
f. Other & unspecified	10	1	2	8	28	21	49	1.8	21.6	2.9	23.6	16.8	0.4	0.7	2.6	8.6	2.4	3.8	35	78	100.0	0.0	
XII OTHER & UNSPECIFIED	5	13	9	22	17	49	66	4.3	100.0	3.9	100.0	8.4	5.5	3.1	7.1	5.2	5.4	5.4	81	108	97.0	3.0	
a. Other specified	0	0	0	1	0	1	1	0.1	2.0	0.1	1.5	-	-	-	0.3	-	0.1	0.1	2	2	100.0	0.0	
b. Other unspecified	5	13	9	21	17	48	65	4.2	98.0	3.9	98.5	8.4	5.5	3.1	6.8	5.2	5.3	5.3	80	106	96.9	3.1	
TOTAL	54	384	337	371	542	1146	1688	100.0	100.0	100.0	100.0	90.7	161.3	115.8	120.5	167.0	129.3	137.8	1917	2752	98.2	1.2	

† includes 31 non-malignant ‡ includes 1 non-malignant

Please consult the quality indicators for the constituent registries

MOROCCO, 2 registries (2005-2012)

	Males										M/F ratio		Females									
	Number of cases in age groups												Number of cases in age groups									
	0	1-4	5-9	10-14	15-19	0-14	0-19	0-14	0-19	0-14	0-19	0	1-4	5-9	10-14	15-19	0-14	0-19	0-14	0-19		
I LEUKAEMIA	5	43	39	35	55	122	177	27.4	28.9	1.9	1.9	0	19	25	20	27	64	91	14.4	14.9		
a. Lymphoid	2	33	26	28	25	89	114	19.9	18.9	2.3	2.1	0	16	17	6	15	39	54	9.2	9.2		
b. Acute myeloid	2	8	7	4	25	21	46	4.8	7.2	1.1	1.7	0	3	6	10	8	19	27	4.0	4.2		
c. CMD	0	0	1	2	4	3	7	0.6	1.0	0.8	1.2	0	0	1	3	2	4	6	0.8	0.9		
d. MDS & other	0	0	2	0	0	2	2	0.4	0.3	-	2.0	0	0	0	0	1	0	1	-	0.1		
e. Unspecified	1	2	3	1	1	7	8	1.6	1.4	3.5	2.7	0	0	1	1	1	2	3	0.4	0.5		
II LYMPHOMA & RELATED	3	24	56	39	80	122	202	26.5	31.7	1.9	1.5	1	9	19	36	71	65	136	13.7	20.4		
a. Hodgkin	0	8	21	14	31	43	74	9.3	11.5	1.2	0.8	0	2	10	24	55	36	91	7.3	13.3		
b. Non-Hodgkin except BL	2	5	13	13	38	33	71	7.1	10.8	1.9	2.4	1	2	5	9	13	17	30	3.6	4.6		
c. Burkitt (BL)	1	9	21	12	7	43	50	9.4	8.3	5.4	5.0	0	4	3	1	2	8	10	1.9	1.8		
d. Lymphoreticular	0	2	0	0	0	2	2	0.5	0.4	2.0	2.0	0	0	1	0	0	1	1	0.2	0.2		
e. Unspecified	0	0	1	0	4	1	5	0.2	0.7	0.3	1.3	0	1	0	2	1	3	4	0.6	0.6		
III CNS NEOPLASMS †	4	31	48	27	17	110	127	24.5	21.4	1.7	1.6	2	14	23	24	17	63	80	13.9	13.2		
a. Ependymoma	0	10	8	3	2	21	23	4.9	4.1	2.6	2.1	0	3	3	2	3	8	11	1.8	1.8		
b. Astrocytoma	0	3	14	7	8	24	32	5.1	5.1	1.2	1.2	1	3	6	10	6	20	26	4.3	4.2		
c. CNS embryonal	2	10	19	7	2	38	40	8.5	6.9	1.9	1.7	0	5	9	6	4	20	24	4.5	4.0		
d. Other gliomas	0	4	2	3	1	9	10	2.0	1.7	3.0	2.0	0	1	2	0	2	3	5	0.7	0.8		
e. Other specified	0	0	0	3	3	3	6	0.6	0.9	0.4	0.6	0	1	1	6	2	8	10	1.6	1.5		
f. Unspecified CNS	2	4	5	4	1	15	16	3.4	2.8	3.8	4.0	1	1	2	0	0	4	4	1.0	0.8		
IV NEUROBLASTOMA	5	25	14	7	1	51	52	12.0	9.5	1.8	1.7	1	20	5	2	3	28	31	7.1	5.9		
a. (Ganglio)neuroblastoma	5	25	14	7	1	51	52	12.0	9.5	1.8	1.7	1	20	5	2	3	28	31	7.1	5.9		
b. Peripheral nervous	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
V RETINOBLASTOMA	4	29	5	1	0	39	39	9.7	7.5	1.2	1.2	1	31	1	0	0	33	33	8.7	6.7		
VI RENAL TUMOURS	1	25	13	2	2	41	43	9.9	7.9	0.7	0.7	3	35	20	3	1	61	62	15.1	11.9		
a. Nephroblastoma	1	25	13	2	2	41	43	9.9	7.9	0.8	0.8	2	30	17	3	0	52	52	12.9	10.0		
b. Renal carcinoma	0	0	0	0	0	0	0	-	-	0.0	0.0	1	4	2	0	1	7	8	1.8	1.5		
c. Unspecified	0	0	0	0	0	0	0	-	-	0.0	0.0	0	1	1	0	0	2	2	0.5	0.4		
VII HEPATIC TUMOURS	0	4	0	3	0	7	7	1.6	1.2	1.8	1.8	2	2	0	0	0	4	4	1.1	0.8		
a. Hepatoblastoma	0	4	0	0	0	4	4	1.0	0.8	1.0	1.0	2	2	0	0	0	4	4	1.1	0.8		
b. Hepatic carcinoma	0	0	0	3	0	3	3	0.6	0.4	-	-	0	0	0	0	0	0	0	-	-		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
VIII BONE TUMOURS	1	4	11	31	46	47	93	9.5	13.8	1.2	1.3	1	3	13	21	32	38	70	8.0	10.6		
a. Osteosarcoma	0	1	2	15	35	18	53	3.5	7.6	1.3	1.7	0	2	4	8	17	14	31	2.9	4.6		
b. Chondrosarcoma	0	0	0	0	1	0	1	-	0.1	-	-	0	0	0	0	0	0	0	-	-		
c. Ewing & related	1	2	8	13	7	24	31	5.0	4.8	1.1	0.9	1	1	9	10	13	21	34	4.4	5.2		
d. Other specified	0	1	1	0	2	2	4	0.5	0.6	-	-	0	0	0	0	0	0	0	-	-		
e. Unspecified	0	0	0	3	1	3	4	0.6	0.6	1.0	0.8	0	0	0	3	2	3	5	0.6	0.7		
IX SOFT TISSUE SARCOMA	1	17	15	19	29	52	81	11.5	12.9	1.5	1.6	0	18	5	11	18	34	52	8.0	8.7		
a. Rhabdomyosarcoma	1	14	13	9	2	37	39	8.4	6.8	1.9	1.6	0	11	3	6	4	20	24	4.7	4.2		
b. Fibrosarcoma	0	1	0	1	4	2	6	0.4	0.9	1.0	1.5	0	1	0	1	2	2	4	0.5	0.6		
c. Kaposi sarcoma	0	0	0	0	1	0	1	-	0.1	-	-	0	0	0	0	0	0	0	-	-		
d. Other specified	0	2	0	7	15	9	24	1.8	3.5	1.8	1.7	0	1	2	2	9	5	14	1.1	2.1		
e. Unspecified	0	0	2	2	7	4	11	0.8	1.6	0.6	1.1	0	5	0	2	3	7	10	1.7	1.7		
X GERM CELL TUMOURS	0	5	0	2	3	7	10	1.7	1.7	0.6	0.4	2	7	0	3	12	12	24	3.0	3.9		
a. CNS germ cell ‡	0	0	0	2	1	2	3	0.4	0.4	2.0	3.0	0	1	0	0	0	1	1	0.3	0.2		
b. Other extragonadal	0	1	0	0	0	1	1	0.3	0.2	0.2	0.1	1	4	0	1	3	6	9	1.5	1.6		
c. Gonadal germ cell	0	4	0	0	1	4	5	1.0	0.9	1.0	0.8	0	2	0	2	2	4	6	0.9	1.0		
d. Gonadal carcinoma	0	0	0	0	1	0	1	-	0.1	-	0.3	0	0	0	0	3	0	3	-	0.4		
e. Unspecified gonadal	0	0	0	0	0	0	0	-	-	0.0	0.0	1	0	0	0	4	1	5	0.3	0.8		
XI CARCINOMA & MELANOMA	6	2	5	36	48	49	97	9.9	14.4	1.0	0.9	6	4	11	27	63	48	111	10.2	16.6		
a. Adrenocortical	0	0	0	0	0	0	0	-	-	0.0	0.0	0	0	0	1	0	1	1	0.2	0.1		
b. Thyroid	0	0	0	1	2	1	3	0.2	0.4	0.1	0.1	0	1	3	3	21	7	28	1.5	4.1		
c. Nasopharyngeal	0	0	1	17	23	18	41	3.4	5.9	1.6	1.7	1	0	0	10	13	11	24	2.2	3.5		
d. Melanoma	0	0	0	0	4	0	4	-	0.6	-	4.0	0	0	0	0	1	0	1	-	0.1		
e. Skin carcinoma	1	1	4	14	10	20	30	4.0	4.5	1.1	1.1	0	3	6	9	9	18	27	3.8	4.2		
f. Other & unspecified	5	1	0	4	9	10	19	2.3	3.0	0.9	0.6	5	0	2	4	19	11	30	2.5	4.6		
XII OTHER & UNSPECIFIED	2	10	4	12	7	28	35	6.2	5.8	1.3	1.1	3	3	5	10	10	21	31	4.6	4.9		
a. Other specified	0	0	0	0	0	0	0	-	-	0.0	0.0	0	0	0	1	0	1	1	0.2	0.1		
b. Other unspecified	2	10	4	12	7	28	35	6.2	5.8	1.4	1.2	3	3	5	9	10	20	30	4.4	4.8		
TOTAL	32	219	210	214	288	675	963	150.3	156.6	1.4	1.3	22	165	127	157	254	471	725	107.8	118.6		

† includes 11 non-malignant in males and 20 non-malignant in females ‡ includes 1 non-malignant in males

Please consult the quality indicators for the constituent registries

MOROCCO, 2 registries (2005-2012)

	Age group	Males	Females
Person-years	0	303 085	292 361
	1-4	1 212 240	1 168 058
	5-9	1 473 705	1 436 238
	10-14	1 544 486	1 534 718
	15-19	1 613 842	1 631 595
Total	0-14	4 533 516	4 431 375
	0-19	6 147 358	6 062 970
Average annual population	0-14	566 690	553 922
	0-19	768 420	757 871

Please consult the quality indicators for the constituent registries

MOROCCO, 2 registries (2005-2012)

Registry	Period	Cases	%	Person-years	%
Casablanca	2005-2012	1496	88.6	10 809 860	88.5
Rabat	2005-2012	192	11.4	1 400 468	11.5
MOROCCO	2005-2012	1688	100.0	12 210 328	100.0

Please consult the quality indicators for the constituent registries

International Incidence of Childhood Cancer Volume III <http://iicc.iarc.fr/results>

Rabat
(2005-2012)

	Cases	0-14		Cases	0-19	
		M/F	ASR		M/F	ASR
I LEUKAEMIA	41	2.2	41.2	46	2.5	34.8
a. Lymphoid	29	1.9	29.1	30	2.0	23.1
b. Acute myeloid	8	3.0	8.3	10	4.0	7.6
c. CMD	2	1.0	1.7	3	2.0	1.9
d. MDS & other	1	.	1.0	1	.	0.7
e. Unspecified	1	.	1.2	2	.	1.5
II LYMPHOMA & RELATED	21	2.5	20.2	34	2.1	23.3
a. Hodgkin	7	0.8	6.2	13	1.2	8.4
b. Non-Hodgkin except BL	2	.	2.1	8	3.0	5.2
c. Burkitt (BL)	8	7.0	7.6	9	3.5	6.5
d. Lymphoreticular	3	2.0	3.3	3	2.0	2.5
e. Unspecified	1	.	1.0	1	.	0.7
III CNS NEOPLASMS †	31	1.4	30.8	33	1.5	25.0
a. Ependymoma	2	.	2.1	2	.	1.6
b. Astrocytoma	8	0.6	8.2	9	0.8	6.9
c. CNS embryonal	7	2.5	7.0	8	3.0	6.0
d. Other gliomas	6	2.0	5.8	6	2.0	4.5
e. Other specified	4	0.3	3.3	4	0.3	2.6
f. Unspecified CNS	4	3.0	4.3	4	3.0	3.3
IV NEUROBLASTOMA	12	2.0	13.5	12	2.0	10.5
a. (Ganglio)neuroblastoma	12	2.0	13.5	12	2.0	10.5
b. Peripheral nervous	0	.	.	0	.	.
V RETINOBLASTOMA	7	2.5	8.1	7	2.5	6.3
VI RENAL TUMOURS	10	2.3	11.4	10	2.3	8.8
a. Nephroblastoma	10	2.3	11.4	10	2.3	8.8
b. Renal carcinoma	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.
VII HEPATIC TUMOURS	1	0.0	1.2	1	0.0	0.9
a. Hepatoblastoma	1	0.0	1.2	1	0.0	0.9
b. Hepatic carcinoma	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.
VIII BONE TUMOURS	9	0.5	8.7	16	1.0	10.9
a. Osteosarcoma	3	0.0	3.0	8	0.6	5.2
b. Chondrosarcoma	0	.	.	1	.	0.6
c. Ewing & related	6	1.0	5.8	7	1.3	5.1
d. Other specified	0	.	.	0	.	.
e. Unspecified	0	.	.	0	.	.
IX SOFT TISSUE SARCOMA	5	1.5	5.5	9	0.8	6.6
a. Rhabdomyosarcoma	5	1.5	5.5	6	1.0	4.8
b. Fibrosarcoma	0	.	.	0	.	.
c. Kaposi sarcoma	0	.	.	0	.	.
d. Other specified	0	.	.	3	0.5	1.8
e. Unspecified	0	.	.	0	.	.
X GERM CELL TUMOURS	3	0.5	3.5	3	0.5	2.7
a. CNS germ cell	0	.	.	0	.	.
b. Other extragonadal	1	0.0	1.2	1	0.0	0.9
c. Gonadal germ cell	2	1.0	2.3	2	1.0	1.8
d. Gonadal carcinoma	0	.	.	0	.	.
e. Unspecified gonadal	0	.	.	0	.	.
XI CARCINOMA & MELANOMA	7	6.0	5.8	18	0.5	11.0
a. Adrenocortical	0	.	.	0	.	.
b. Thyroid	1	.	0.8	5	0.3	3.0
c. Nasopharyngeal	2	.	1.7	5	0.7	3.1
d. Melanoma	0	.	.	0	.	.
e. Skin carcinoma	2	.	1.7	2	.	1.3
f. Other & unspecified	2	1.0	1.7	6	0.2	3.6
XII OTHER & UNSPECIFIED	3	0.5	3.0	3	0.5	2.3
a. Other specified	0	.	.	0	.	.
b. Other unspecified	3	0.5	3.0	3	0.5	2.3
TOTAL	150	1.7	152.6	192	1.5	143.0

† includes 7 non-malignant in Rabat

Please consult the quality indicators for the constituent registries